No Prescription |
 |
 | ||
|
Nalcrom Intal |
|
| ||
No Prescription » Prescription Drugs 11 » Nalcrom Intal Cromolyn is used to prevent the wheezing shortness of breath and troubled breathing caused by asthma. It also is used to prevent breathing difficulties (bronchospasm) during exercise. It works by preventing the release of substances that cause inflammation (swelling) in the air passages of the lungs.Cromolyn comes as a solution and an aerosol to inhale by mouth. It is usually inhaled three or four times a day to prevent asthma attacks or within an hour before activities to prevent breathing difficulties caused by exercise.Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Use cromolyn exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.It may take up to 4 weeks for cromolyn to work. You should use it regularly for it to be effective. If your symptoms have not improved after 4 weeks tell your doctor.Cromolyn is used with a special inhaler. Before you use cromolyn inhalation for the first time read the instructions for your device. Ask your doctor pharmacist or respiratory therapist to demonstrate the proper technique. Practice using your inhalation device while in his or her presence. Buy Nalcrom Intal and other Prescription Drugs 11 products online at Medstore. 186
About Nalcrom Intal: Product Type: Prescription Drugs 11 Nalcrom ( Intal Generic Sodium Cromoglycate ) Nalcrom (Intal Generic Sodium Cromoglycate) Intal Generic Sodium Cromoglycate 100mg 100 CAPSULES Intal Generic Sodium Cromoglycate Nalcrom
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
